Drug Profile

GLG 302

Alternative Names: GLG-302

Latest Information Update: 28 Nov 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dana-Farber Cancer Institute; H. Lee Moffitt Cancer Center and Research Institute
Developer GLG Pharma
Class Antineoplastics; Small molecules
Mechanism of Action STAT3 transcription factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Triple negative breast cancer

Most Recent Events

28 Nov 2021 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in USA (PO, Suspension)
20 Apr 2020 GLG Pharma plans to file an IND application for phase I development in Breast cancer (PO) (GLG Pharma pipeline, April 2020)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com